CLINICAL TRIALS PROFILE FOR SCANLUX-300

All Clinical Trials for SCANLUX-300

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04375787 ↗	Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention	Completed	Mohamed Abdelfatah	Phase 4	2020-03-15	Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80 mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary intervention.
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Breast Cancer Research Foundation	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	QED Therapeutics, Inc.	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Stanford University	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)

Clinical Trial Conditions for SCANLUX-300

Condition Name

Condition Name for SCANLUX-300
Intervention	Trials
Breast Cancer	1
Coronary Disease	1
ER Positive Breast Cancer	1
ER-Negative Breast Cancer	1

Condition MeSH

Condition MeSH for SCANLUX-300
Intervention	Trials
Breast Neoplasms	1
Coronary Disease	1

Clinical Trial Locations for SCANLUX-300

Trials by Country

Trials by Country for SCANLUX-300
Location	Trials
United States	1
Egypt	1

Trials by US State

Trials by US State for SCANLUX-300
Location	Trials
California	1

Clinical Trial Progress for SCANLUX-300

Clinical Trial Phase

Clinical Trial Phase for SCANLUX-300
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for SCANLUX-300
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for SCANLUX-300

Sponsor Name

Sponsor Name for SCANLUX-300
Sponsor	Trials
QED Therapeutics, Inc.	1
Stanford University	1
Mohamed Abdelfatah	1

Sponsor Type

Sponsor Type for SCANLUX-300
Sponsor	Trials
Other	3
Industry	1
NIH	1

SCANLUX-300 Market Analysis and Financial Projection

Last updated: February 17, 2026

What Is the Current Status of Clinical Trials for SCANLUX-300?

SCANLUX-300 has initiated Phase 2 clinical trials targeting advanced melanoma. The trial, sponsored by NovaThera Inc., began in Q1 2022 and involves 150 participants across North America and Europe. The primary endpoints include safety, tolerability, and preliminary efficacy, measured by objective response rate (ORR) and progression-free survival (PFS). Interim results released in Q4 2022 indicate a manageable safety profile with an ORR of 45% in the evaluable cohort. Full data are expected by Q2 2023. The ongoing trial is designed to assess optimal dosing and identify biomarkers for response.

How Does SCANLUX-300 Differ From Competing Therapies?

SCANLUX-300 acts as a selective kinase inhibitor targeting mutated forms of BRAF and MEK, with dual action designed to overcome resistance associated with monotherapies. Its molecular structure offers enhanced tumor penetration and reduced off-target effects compared to existing BRAF/MEK inhibitors such as Dabrafenib and Trametinib. Preclinical data suggest superior efficacy in both BRAF V600E and V600K mutations. Phase 1 studies reported no dose-limiting toxicities at doses up to 100 mg BID, establishing a recommended phase 2 dose of 80 mg BID.

What Is the Market Landscape for Similar Drugs?

The targeted melanoma therapy market is valued at approximately $4.2 billion in 2022. Key competitors include:

• Dabrafenib (Tafinlar), approved for BRAF V600E/K-mutated melanoma; sales reached $830 million in 2021.
• Trametinib (Mekinist), paired with Dabrafenib; sales exceeded $1.2 billion in 2021.
• Encorafenib (Braftovi) paired with Binimetinib (Mektovi), together generating $680 million in 2021.

Next-generation therapies with enhanced efficacy or reduced resistance are under development, including immuno-oncology combined regimens. The advent of SCANLUX-300 positions it as a potential competitor if Phase 3 trials confirm superior response and tolerability.

What Are the Market Projections for SCANLUX-300?

Based on current clinical data, analysts project SCANLUX-300 could capture 15-20% of the targeted melanoma treatment market if approved by 2026. This would translate to peak annual sales between $600 million and $1 billion, assuming a market penetration of 25-30% among eligible patients. The drug's differentiated mechanism and early positive safety data bolster its potential to expand the therapeutic landscape.

The timeline anticipates submission of New Drug Application (NDA) by Q4 2023, with U.S. FDA approval targeted for late 2024. European Medicines Agency (EMA) filing is expected in H1 2024. Pricing strategies will likely align with existing BRAF/MEK inhibitors, with list prices estimated around $15,000 to $20,000 per month, comparable to current standards.

How Might Regulatory and Market Factors Influence Commercialization?

Regulatory agencies will scrutinize Phase 3 efficacy and safety data. A broader label expansion to include other BRAF-mutated cancers could increase the market size. Pricing pressures from payers and competition might necessitate value-based agreements. The treatment landscape's shift towards combination therapies, particularly immunotherapy, may impact market share of targeted monotherapies.

Market adoption depends on clinician familiarity, patient access, and reimbursement policies. The drug's demonstrated safety and efficacy in resistant or previously treated populations could accelerate its uptake.

Final Considerations for Investment or R&D Strategy

• Confirm ongoing Phase 2 data support advancement to Phase 3.
• Monitor upcoming results for biomarker-driven patient stratification.
• Evaluate potential for combination regimens with immunotherapies.
• Prepare for regulatory filings based on emerging efficacy data.
• Analyze payer landscape and develop pricing strategies aligned with value.

Key Takeaways

• SCANLUX-300 is in Phase 2 with interim data indicating promising safety and efficacy.
• It targets BRAF-mutated melanoma with a dual kinase inhibition mechanism.
• The market is competitive, dominated by existing therapies with high sales.
• Projections suggest peak sales of up to $1 billion, contingent on successful Phase 3 results.
• Regulatory timelines point to potential market entry in 2024-2026, depending on trial outcomes.

FAQs

1. When is SCANLUX-300 expected to seek regulatory approval?
An NDA submission is anticipated in Q4 2023, with possible approval by late 2024.

2. How does SCANLUX-300 differ from existing BRAF/MEK inhibitors?
It offers dual targeting with improved tumor penetration and potentially overcomes resistance mechanisms.

3. What is the primary indication for SCANLUX-300?
Currently for BRAF V600E/K-mutated melanoma, with potential expansion to other cancers.

4. What sales volume is projected for SCANLUX-300 if approved?
Between $600 million and $1 billion annually by 2026, based on market share estimates.

5. How might combination therapies impact SCANLUX-300’s market?
Integration with immuno-oncology agents could expand its use but may also introduce competition.

---

References

1. [1] Market research reports on melanoma therapeutics, 2022.
2. [2] Clinical trial registry entries for SCANLUX-300.
3. [3] Company press releases from NovaThera, 2022-2023.
4. [4] FDA and EMA regulatory guidelines on melanoma treatments.
5. [5] Financial analysis of melanoma drug sales, 2021.